Key inclusion criteria
• Documented histological or cytological
diagnosis of RCC with a clear cell component
• Karnofsky Performance Score (KPS) ≥ 70%
• Measurable disease per RECIST 1.1
1-2 lines of prior therapy for advanced
or metastatic clear cell RCC, including
at least 1 anti-angiogenic therapy
or nivolumab + ipilimumab
Randomization
Placebo +
cabozantinib
CB-839 +
cabozantinib
Primary endpoint
Progression-free survival
Key exclusion criteria
•
•
•
•
•
www.calithera.com
CANTATA
NOW ENROLLING
CB-839 in RCC
For more details about the CANTATA
clinical trial or to refer patients:
Call: 1-650-870-1028
Visit: www.cantatatrial.com
Email: clinicaltrials@calithera.com
Calithera Biosciences—Our onco-metabolism
approach brings an enhanced perspective to cancer.
© 2018 Calithera. The CALITHERA name is a registered trademark
of Calithera Biosciences, Inc. All Rights Reserved.
NCT03428217
CB-839 is an investigational product and is not approved in the United States or any other country.
/www.calithera.com
/www.cantatatrial.com
link